DOCSLIB.ORG

Consideration of Antibacterial Medicines As Part Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Consideration of Antibacterial Medicines As Part Of Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1. The revised lists of essential medicines are available here: - World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO (https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06- eng.pdf?ua=1). - World Health Organization Model List of Essential Medicines for Children, 7th List, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO (https://apps.who.int/iris/bitstream/handle/10665/325772/WHO-MVP-EMP-IAU-2019.07- eng.pdf?ua=1). Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for Europe UN City, Marmorvej 51 DK-2100 Copenhagen Ø, Denmark Alternatively, complete an online request form for documentation, health information, or for permission to quote or translate, on the Regional Office website (http://www.euro.who.int/pubrequest). © World Health Organization 2020 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc), Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics.Copenhagen: WHO Regional Office for Europe; 2020. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing. Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user. General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use. The recommendations contained in this publication are based on the advice of independent experts, who have considered the best available evidence, a risk–benefit analysis and other factors, as appropriate. This publication may include recommendations on the use of medicinal products for an indication, in a dosage form, dose regimen, population or other use parameters that are not included in the approved labelling. Relevant stakeholders should familiarize themselves with applicable national legal and ethical requirements. WHO does not accept any liability for the procurement, distribution and/or administration of any product for any use. Introduction This Summary reports the recommendations made by the 2019 WHO Expert Committee on the Selection and Use of Essential Medicines for Section 6.2 antibacterials, describes the deliberations of the EML Antibiotics Working Group, outlines changes to the Access, Watch and Reserve (AWaRe) classification of antibiotics and reports the list of discouraged antibiotics. The Expert Committee: ● restructured Section 6.2 to align with the AWaRe classification, replacing the sub-sections based on chemical structure (e.g. beta-lactam and other antibacterials) ● added new indications for existing medicines on the EML and EMLc namely, medicines for typhoid and paratyphoid (enteric) fever; for surgical prophylaxis and for oral and dental infections ● recommended the addition of 4 new medicines – cefuroxime for surgical prophylaxis (EML, EMLc); ceftazidime + avibactam, meropenem + vaboractam and plazomicin as Reserve last- resort antibiotics for multi-drug resistant infections (EML) ● rejected applications for the addition of ceftolozone + tazobactam, delafloxacin, eravacycline and omadacycline as last-resort antibiotics ● removed aztreonam, fourth- and fifth-generation cephalosporins (as classes), tigecycline and daptomycin from the Reserve complementary list of the EML and EMLc ● reclassified fourth-generation cephalosporins as Watch group ● reclassified faropenem from Watch to Reserve group ● based on the advice of the EML Antibiotics Working Group, nominated a number of agents as ‘not recommended’ agents; these are antibiotics whose use is not evidence-based, nor recommended in high quality international guidelines, particularly fixed-dose combinations of multiple broad-spectrum antibiotics. Recognizing that the EML-listed antibiotics represented a small set of narrow spectrum antibiotics for first- and second-choice empiric treatment of common infections, the Expert Committee endorsed the recommendations of the EML Antibiotics Working Group to classify 177 commonly used antibiotics to Access, Watch and Reserve groups. A database of the 177 agents with ATC codes has been created (https://www.who.int/medicines/publications/essentialmedicines/en/ ). A new target indicator based on the AWaRe classification was adopted which specifies a country-level target of at least 60% of antibiotic consumption being from the Access group. A summary of the clinical syndromes reviewed by the Expert Committees in 2017 and 2019 is provided in Annex 1. 4 Revised structure of Section 6.2 antibacterials The Expert Committee recommended the re-structuring of Section 6.2 to better accommodate the AWaRe classification, and that antibiotics on the EML be listed in revised sub-sections according to AWaRe groups, replacing the existing sub-sections based on chemical structure (e.g., beta-lactam and other antibacterials). The revised structure is: − 6.2.1: Access group antibiotics − 6.2.2: Watch group antibiotics − 6.2.3: Reserve
Load more

Recommended publications
  • A Computational Drug Repositioning Case Study Prashant S. Kharkar1*, Ponnadurai Ramasami2, Yee S
    Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2016 Discovery of Anti-Ebola Drugs: A Computational Drug Repositioning Case Study Prashant S. Kharkar1*, Ponnadurai Ramasami2, Yee Siew Choong3, Lydia Rhyman2 and Sona Warrier1 1SPP School of Pharmacy and Technology Management, SVKM’s NMIMS, V. L. Mehta Road, Vile Parle (West), Mumbai-400 056. INDIA. 2 Computational Chemistry Group, Department of Chemistry, Faculty of Science, University of Mauritius, Réduit 80837, Mauritius 3Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Malaysia Contents Sr. No. Description Page No. 1 Table 1S 1 2 Figure 1S 28 3 Figure 2S 29 4 Figure 3S 30 5 Figure 4S 31 6 Figure 5S 32 Table 1S. Top hits (#100) identified from EON screening using query 1 Estimated Sr. EON_ Shape Free Energy Drug Structure ET_pb ET_coul ET_combo Rank No. Tanimoto of Binding (kcal/mol) OH O Br N O 1 1 S -9.88 HO O O O S O O 2 Sitaxentan S 0.633 0.914 0.926 0.294 1 -14.37 HN O Cl O N O HO 3 Alitretinoina 0.66 0.91 0.906 0.246 2 -3.91 NH 2 S N N O O HN 4 Ceftriaxone S 0.606 0.937 0.823 0.217 3 -12.33 N O S N O HO O N N O H O a 5 Acitretin O 0.637 0.936 0.809 0.172 4 -3.71 OH HO NH 2 HO N N 6 Cidofovir P O 0.473 0.633 0.783 0.31 5 -4.21 HO O O N N N N 7 Telmisartan 0.601 0.908 0.775 0.174 6 -6.46 OH O 8 Nateglinidea HN 0.54 0.874 0.745 0.205 7 -3.78 OH O O H N 2 S OH N O N S O 9 Ceftizoxime N 0.557 0.88 0.735 0.178 8 -11.35 H O N O OH O 10 Treprostinil OH 0.432 0.846 0.732 0.301 9 -3.41 O HO O O S
    [Show full text]
  • Mediated Peptidoglycan Cross-Linking and B-Lactam Resistance In
    RESEARCH ARTICLE Factors essential for L,D-transpeptidase- mediated peptidoglycan cross-linking and b-lactam resistance in Escherichia coli Jean-Emmanuel Hugonnet1,2,3, Dominique Mengin-Lecreulx4, Alejandro Monton5, Tanneke den Blaauwen5, Etienne Carbonnelle1,2,3, Carole Veckerle´ 1,2,3, Yves, V. Brun6, Michael van Nieuwenhze6, Christiane Bouchier7, Kuyek Tu1,2,3, Louis B Rice8, Michel Arthur1,2,3* 1INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France; 2Sorbonne Universite´s, UPMC Universite´ Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France; 3Universite´ Paris Descartes, Sorbonne Paris Cite´, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France; 4Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Universite´ Paris-Sud, Universite´ Paris-Saclay, Gif-sur-Yvette, France; 5Bacterial Cell Biology and Physiology, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, Netherlands; 6Indiana University, Indiana, United States; 7Institut Pasteur, Paris, France; 8Rhode Island Hospital, Brown University, Providence, United States Abstract The target of b-lactam antibiotics is the D,D-transpeptidase activity of penicillin- binding proteins (PBPs) for synthesis of 4fi3 cross-links in the peptidoglycan of bacterial cell walls. Unusual 3fi3 cross-links formed by L,D-transpeptidases were first detected in Escherichia coli more than four decades ago, however no phenotype has previously been associated with their synthesis. Here we show that production of the L,D-transpeptidase YcbB in combination with elevated *For correspondence: michel. synthesis of the (p)ppGpp alarmone by RelA lead to full bypass of the D,D-transpeptidase activity [email protected] of PBPs and to broad-spectrum b-lactam resistance.
    [Show full text]
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • Redalyc.Patterns of Antimicrobial Therapy in Acute Tonsillitis: a Cross
    Anais da Academia Brasileira de Ciências ISSN: 0001-3765 [email protected] Academia Brasileira de Ciências Brasil JOHN, LISHA J.; CHERIAN, MEENU; SREEDHARAN, JAYADEVAN; CHERIAN, TAMBI Patterns of Antimicrobial therapy in acute tonsillitis: A cross-sectional Hospital-based study from UAE Anais da Academia Brasileira de Ciências, vol. 86, núm. 1, enero-marzo, 2014, pp. 451-457 Academia Brasileira de Ciências Rio de Janeiro, Brasil Available in: http://www.redalyc.org/articulo.oa?id=32730090032 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative Anais da Academia Brasileira de Ciências (2014) 86(1): 451-457 (Annals of the Brazilian Academy of Sciences) Printed version ISSN 0001-3765 / Online version ISSN 1678-2690 http://dx.doi.org/10.1590/0001-3765201420120036 www.scielo.br/aabc Patterns of Antimicrobial therapy in acute tonsillitis: A cross-sectional Hospital-based study from UAE LISHA J. JOHN1, MEENU CHERIAN2, JAYADEVAN SREEDHARAN3 and TAMBI CHERIAN2 1Department of Pharmacology, Gulf Medical University, 4184, Ajman, United Arab Emirates 2Department of ENT, Gulf Medical College Hospital, 4184, Ajman, United Arab Emirates 3Statistical Support Facility, Centre for Advanced Biomedical Research and Innovation, Gulf Medical University, 4184, Ajman, United Arab Emirates Manuscript received on December 20, 2012; accepted for publication on October 14, 2013 ABSTRACT Background: Diseases of the ear, nose and throat (ENT) are associated with significant impairment of the daily life and a major cause for absenteeism from work.
    [Show full text]
  • Cefalexin in the WHO Essential Medicines List for Children Reject
    Reviewer No. 1: checklist for application of: Cefalexin In the WHO Essential Medicines List for Children (1) Have all important studies that you are aware of been included? Yes No 9 (2) Is there adequate evidence of efficacy for the proposed use? Yes 9 No (3) Is there evidence of efficacy in diverse settings and/or populations? Yes 9 No (4) Are there adverse effects of concern? Yes 9 No (5) Are there special requirements or training needed for safe/effective use? Yes No 9 (6) Is this product needed to meet the majority health needs of the population? Yes No 9 (7) Is the proposed dosage form registered by a stringent regulatory authority? Yes 9 No (8) What action do you propose for the Committee to take? Reject the application for inclusion of the following presentations of cefalexin: • Tablets/ capsules 250mg • Oral suspensions 125mg/5ml and 125mg/ml (9) Additional comment, if any. In order to identify any additional literature, the following broad and sensitive search was conducted using the PubMed Clinical Query application: (cephalexin OR cefalexin AND - 1 - pediatr*) AND ((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading]) Only one small additional study was identified, which looked at the provision of prophylactic antibiotics in patients presenting to an urban children's hospital with trauma to the distal fingertip, requiring repair.1 In a prospective randomised control trial, 146 patients were enrolled, of which 69 were randomised to the no-antibiotic group, and 66 were randomised to the antibiotic (cefalexin) group.
    [Show full text]
  • Ultraviolet-Visible Reference Spectra C
    1536 Ultraviolet-visible Reference Spectra JP XV Butropium Bromide 1 A solution in methanol (1 in 100,000) Butropium Bromide 2 A solution in methanol (1 in 5000) Calcium Folinate An aqueous solution (1 in 100,000) JP XV Ultraviolet-visible Reference Spectra 1537 Camostat Mesilate An aqueous solution (1 in 100,000) Carbamazepine The sample solution obtained in the Assay Carbazochrome Sodium Sulfonate Hydrate An aqueous solution (1 in 100,000) 1538 Ultraviolet-visible Reference Spectra JP XV Carbidopa Hydrate A solution prepared as follows: Dissolve 0.01 g in 250 mL of a solution of hydrochloric acid in methanol (9 in 1000) Carmofur A solution in a mixture of methanol and phosphoric acid-acetic acid-boric acid buffer solution, pH 2.0 (9:1) (1 in 100,000) Carteolol Hydrochloride An aqueous solution (1 in 100,000) JP XV Ultraviolet-visible Reference Spectra 1539 Carumonam Sodium An aqueous solution (3 in 100,000) Cefaclor An aqueous solution (1 in 50,000) Cefadroxil An aqueous solution (1 in 50,000) 1540 Ultraviolet-visible Reference Spectra JP XV Cefalexin An aqueous solution (3 in 100,000) Cefalotin Sodium An aqueous solution (1 in 50,000) Cefapirin Sodium An aqueous solution (3 in 200,000) JP XV Ultraviolet-visible Reference Spectra 1541 Cefatrizine Propylene Glycolate An aqueous solution (1 in 50,000) Cefazolin Sodium An aqueous solution (1 in 50,000) Cefbuperazone Sodium An aqueous solution (1 in 50,000) 1542 Ultraviolet-visible Reference Spectra JP XV Cefditoren Pivoxil A solution in methanol (1 in 50,000) Cefixime A solution in 0.1
    [Show full text]
  • United States Patent ( 10 ) Patent No.: US 10,561,6759 B2 Griffith Et Al
    US010561675B2 United States Patent ( 10 ) Patent No.: US 10,561,6759 B2 Griffith et al. (45 ) Date of Patent : * Feb . 18 , 2020 (54 ) CYCLIC BORONIC ACID ESTER ( 58 ) Field of Classification Search DERIVATIVES AND THERAPEUTIC USES CPC A61K 31/69 ; A61K 31/396 ; A61K 31/40 ; THEREOF A61K 31/419677 (71 ) Applicant: Rempex Pharmaceuticals , Inc. , (Continued ) Lincolnshire , IL (US ) (56 ) References Cited (72 ) Inventors : David C. Griffith , San Marcos, CA (US ) ; Michael N. Dudley , San Diego , U.S. PATENT DOCUMENTS CA (US ) ; Olga Rodny , Mill Valley , CA 4,194,047 A 3/1980 Christensen et al . ( US ) 4,260,543 A 4/1981 Miller ( 73 ) Assignee : REMPEX PHARMACEUTICALS , ( Continued ) INC . , Lincolnshire , IL (US ) FOREIGN PATENT DOCUMENTS ( * ) Notice : Subject to any disclaimer, the term of this EP 1550657 A1 7/2005 patent is extended or adjusted under 35 JP 2003-229277 A 8/2003 U.S.C. 154 ( b ) by 1129 days. (Continued ) This patent is subject to a terminal dis claimer . OTHER PUBLICATIONS Abdel -Magid et al. , “ Reductive Amination ofAldehydes and Ketones ( 21) Appl. No .: 13 /843,579 with Sodium Triacetoxyborohydride: Studies on Direct and Indirect Reductive Amination Procedures ” , J Org Chem . ( 1996 )61 ( 11 ): 3849 ( 22 ) Filed : Mar. 15 , 2013 3862 . (65 ) Prior Publication Data (Continued ) US 2013/0331355 A1 Dec. 12 , 2013 Primary Examiner — Shengjun Wang Related U.S. Application Data (74 ) Attorney, Agent, or Firm — Wilmer Cutler Pickering (60 ) Provisional application No.61 / 656,452 , filed on Jun . Hale and Dorr LLP 6 , 2012 (57 ) ABSTRACT (51 ) Int. Ci. A61K 31/69 ( 2006.01) Method of treating or ameliorating a bacterial infection A61K 31/00 ( 2006.01 ) comprising administering a composition comprising a cyclic (Continued ) boronic acid ester compound in combination with a car ( 52 ) U.S.
    [Show full text]
  • 00246-2019.Supptables
    1 Table S1. List of ICD-10 codes identifying comorbidities during hospitalization for COPD exacerbation COPD J41, J42, J43, J440, J441, J449 COPD exacerbation J10, J11, J13, J14, J15, J16, J18, J20, J21, J22, J46, J170, J171, J178, J440, J441, J851, J12, A481, B012, B052, B250 Bacterial pneumonia J100, J110, J12, J13, J14, J15, J16, J170, J178, J18, J851, A481 Lung cancer C34 Other malignancy C00-26, C30-33, C37-41, C43-58, C60-76 Diabetes/abnormal glucose tolerance E10-14, R703 Bone fracture/osteoporosis M80-84 Interstitial pneumonia B221, J701, J704, J841, J848, J849, J990, J991, M321, M330, M331, M332, M351 Bronchial asthma J45, J46 Bronchiectasis J40, J41, J42, J47 Pulmonary thromboembolism I26 Mycobacterium infection A150-154, A156-159, A161-162, A165, A168-169, A19, A310, A319 Mycotic infection A420, A43, B37, B380-382, B390-392, B400-402, B410, B420, B440, B441, B449, B460, J172 Cor pulmonare I27 Congestive heart failure E059, I46, I50, I099, I110 Ischemic heart disease I20-25 Tachycardia I47-49, R000, T818 Autoimmune disease M05, M06, M08, M30-35 Stroke I60-64 Liver dysfunction B89, B181, B182, B659, B661, K702, K703, K72, K74, K761, K762, K763, K766, K767 Renal failure E102, E112, E142, I120, N17-19 GERD K21 Constipation or ileus K56, K590 Prostate hypertrophy N40 Abbreviations: COPD, chronic obstructive pulmonary disease; GERD, gastro-esophageal reflux disease 2 Table S2. List of baseline characteristics, comorbidities, and treatments before and during hospitalization for COPD exacerbation Baseline characteristics Sex, fiscal
    [Show full text]
  • Download Download
    VOLUME 7 NOMOR 2 DESEMBER 2020 ISSN 2548 – 611X JURNAL BIOTEKNOLOGI & BIOSAINS INDONESIA Homepage Jurnal: http://ejurnal.bppt.go.id/index.php/JBBI IN SILICO STUDY OF CEPHALOSPORIN DERIVATIVES TO INHIBIT THE ACTIONS OF Pseudomonas aeruginosa Studi In Silico Senyawa Turunan Sefalosporin dalam Menghambat Aktivitas Bakteri Pseudomonas aeruginosa Saly Amaliacahya Aprilian*, Firdayani, Susi Kusumaningrum Pusat Teknologi Farmasi dan Medika, BPPT, Gedung LAPTIAB 610-612 Kawasan Puspiptek, Setu, Tangerang Selatan, Banten 15314 *Email: [email protected] ABSTRAK Infeksi yang diakibatkan oleh bakteri gram-negatif, seperti Pseudomonas aeruginosa telah menyebar luas di seluruh dunia. Hal ini menjadi ancaman terhadap kesehatan masyarakat karena merupakan bakteri yang multi-drug resistance dan sulit diobati. Oleh karena itu, pentingnya pengembangan agen antimikroba untuk mengobati infeksi semakin meningkat dan salah satu yang saat ini banyak dikembangkan adalah senyawa turunan sefalosporin. Penelitian ini melakukan studi mengenai interaksi tiga dimensi (3D) antara antibiotik dari senyawa turunan Sefalosporin dengan penicillin-binding proteins (PBPs) pada P. aeruginosa. Tujuan dari penelitian ini adalah untuk mengklarifikasi bahwa agen antimikroba yang berasal dari senyawa turunan sefalosporin efektif untuk menghambat aktivitas bakteri P. aeruginosa. Struktur PBPs didapatkan dari Protein Data Bank (PDB ID: 5DF9). Sketsa struktur turunan sefalosporin digambar menggunakan Marvins Sketch. Kemudian, studi mengenai interaksi antara antibiotik dan PBPs dilakukan menggunakan program Mollegro Virtual Docker 6.0. Hasil yang didapatkan yaitu nilai rerank score terendah dari kelima generasi sefalosporin, di antaranya sefalotin (-116.306), sefotetan (-133.605), sefoperazon (-160.805), sefpirom (- 144.045), dan seftarolin fosamil (-146.398). Keywords: antibiotik, penicillin-binding proteins, P. aeruginosa, sefalosporin, studi interaksi ABSTRACT Infections caused by gram-negative bacteria, such as Pseudomonas aeruginosa, have been spreading worldwide.
    [Show full text]
  • Cefixime (Suprax) Division of Disease Control What Do I Need to Know?
    Division of Disease Control What Do I Need To Know? Cefixime (Suprax) About your medicine: Cefixime is used to treat bacterial infections in many different parts of the body. This medicine will not work for colds, flu, or other viral infections. It may be used to other problems as determined by your healthcare provider. These instructions will help you receive the optimum benefits from Cefixime. Before taking this medication: Tell your doctor, nurse or healthcare provider if you… . Have any allergies to medications (especially cephalosporins and penicillin) . Take any other medications . Have medical condition (especially kidney or eye problems) . Are pregnant, breast-feeding or trying to become pregnant . History of convulsions Possible side effects of this medicine: If these symptoms continue or become severe, call your health care provider… . Nausea, vomiting, diarrhea . Gas . Indigestion . Dyspepsia (upset stomach) . Abdominal pain . Muscle cramps, stiffness, spasms . If your symptoms do not improve within a few days, notify your healthcare provider How to take this medicine: . This is the only dose of this medicine you will receive . Take this medication with a full glass (8 ounces) of water, preferably after a meal . DO NOT take with milk or other dairy products, or any products containing magnesium or calcium (such as antacids), iron or aluminum within 2 hours of the time you take this medicine . Drink several additional glasses of water today Warning: Call a healthcare professional immediately if you develop any of the following: . Difficulty breathing . Hives/skin rash Sexual Behavior: Abstain from any type of sexual activity for 7 days after treatment of self and partner For more information, contact the NDDoH STD Program at 701.328.2378 or toll-free 800.472.2180 Page 1 of 1 Last Updated: 4/3/2012 .
    [Show full text]
  • AMR Surveillance in Pharma: a Case-Study for Data Sharingauthor by Professor Barry Cookson
    AMR Open Data Initiative AMR Surveillance in Pharma: a case-study for data sharingauthor by Professor Barry Cookson External Consultant to Project eLibrary • Division of Infection and Immunity, Univ. College London ESCMID• Dept. of Microbiology, © St Thomas’ Hospital Background of “90 day Project” Addressed some recommendations of the first Wellcome funded multi-disciplinary workshop (included Pharma Academia & Public Health invitees: 27thauthor July 2017 (post the Davos Declaration): by 1) Review the landscape of existing Pharma AMR programmes, their protocols,eLibrary data standards and sets 2) Develop a "portal" (register/platform) to access currently available AMR Surveillance data ESCMID Important ©to emphasise that this is a COLLABORATION between Pharma and others Overview of Questionnaire Content • General information - including name,author years active, countries, antimicrobials, microorganisms.by • Methodology - including accreditation, methodology for; surveillance, isolate collection, organism identification, breakpointseLibrary used, • Dataset - including data storage methodology, management and how accessed. ESCMID © 13 Company Responses author 7 by 3 3 eLibrary ESCMID © Structure of register Companies can have different ways of referring to their activities: We had to choose a consistent framework. author Companies Companyby 1 Programmes Programme A Programme B eLibrary Antimicrobials 1 2 3 4 5 company’s product comparator company’s product antimicrobials Programmes canESCMID contain multiple studies (e.g. Pfizer has© single
    [Show full text]
  • Breeding Laboratories (Hino, Japan)
    VOL. XLII NO. 6 THE JOURNAL OF ANTIBIOTICS 989 STIMULATORY EFFECT OF CEFODIZIME ON MACROPHAGE- MEDIATED PHAGOCYTOSIS Kazunori Oishi, Keizo Matsumoto, Masashi Yamamoto, Toshihiro Morito and Toshiaki Yoshida Department of Internal Medicine, Institute of Tropical Medicine, Nagasaki University, 12-4 Sakamoto-machi, Nagasaki 852, Japan (Received for publication January 27, 1989) Weevaluated the ingestion of anti-sheep erythrocyte (anti-E) IgG- and IgM-coated sheep erythiocytes by murineperitoneal macrophagesexposed to cefodizime, a newsemisynthetic cephalosporin, and other antibiotics. Cefodizime enhanced the ingestion of anti-E IgG- coated erythrocytes by peritoneal macrophages from CD-I and BALB/cmice in a dose- dependent manner, but had no effect on uncoated or IgM-coated erythrocytes. Similar enhancement was observed only in the case of cefpimizole (AC-1370), among the other anti- biotics examined. These results suggest that the favorable in vivo activity of cefodizime and cefpimizole may result from their phagocytosis-enhancing as well as antimicrobial properties. The new semisynthetic cephalosporin, cefodizime, is characterized by a cephem ring which con- tains a ^w-methoxyimino-aminothiazolyl group at the 7-position and a thiazolylthio-methyl group at the 3-position. The latter substitution is thought to provide metabolic stability and a prolonged half-life in humanserum0. The efficacy of cefodizime in experimental murine infections is apparently superior to that predicted from in vitro activity2>3). Wepostulated that the enhanced in vivo activity of cefodizime may be due to drug-induced immunostimulation. This speculation was in part based upon the previous demonstration that a variety of agents, including lysophosphatidylcholine4) and fibronectin5), enhance receptor-dependent phagocytosis. Moreover, it was previously reported that cefpimizole (AC-1370), another semisynthetic cephalosporin, potentiated phagocyte function of macrophages and neutrophils6).
    [Show full text]